Physician profile
Jaid Lyons
NPI 1154035822
$6,461.63
in general payments reported to CMS, 2019-2025
28 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,849 · 2024: $2,281 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,351 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,350.83 |
| Education | $110.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $891.70 | 2023-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $775.29 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $710.67 | 2023-2025 | Farxiga, Wainua, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $541.47 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $526.61 | 2023-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $439.31 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $315.39 | 2023-2024 | Xarelto |
| Pfizer INC. | $254.45 | 2023-2025 | |
| Amgen INC. | $250.04 | 2023-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $239.04 | 2023-2025 | Evkeeza |
| United Therapeutics Corporation | $234.52 | 2023-2024 | Tyvaso, Orenitram, Remodulin |
| Novo Nordisk INC | $199.22 | 2023-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $172.26 | 2023-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $168.26 | 2023-2025 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $125.27 | 2023-2024 | Inpefa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $123.91 | 2023-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $107.73 | 2023-2024 | |
| Impulse Dynamics (USA) INC. | $81.92 | 2023-2024 | Optimizer, Optimizer |
| Abiomed | $81.14 | 2024-2025 | Impella |
| Chiesi USA, INC. | $39.83 | 2025 | Juxtapid |
| Alnylam Pharmaceuticals INC. | $35.08 | 2025 | Amvuttra |
| Cvrx, INC. | $32.99 | 2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals, Ltd. | $29.70 | 2023 | Arcalyst |
| Medicomp INC | $21.42 | 2023 | Telepatch Cardiac Monitor |
| Philips North America LLC | $19.47 | 2024 | (Ck4) Mcot |
| Scpharmaceuticals INC. | $16.57 | 2023 | |
| Baxter Healthcare | $14.31 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $14.06 | 2025 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaid Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.